As per the Centre for Disease Control and Prevention (CDC) report, people with depressive disorder increased from 36.4% to 41.5% from August 2020 to February 2021, and adults between the age group of 18-29 are the most affected.

 

United States. A leading biotech company, Mind Medicine, has planned to build a strategic alliance with a mental health service provider, Sphere Health. The companies have partnered to improve the understanding of various biomarkers related to mental health illness. The plan is to jointly launch MM061302, a study utilizing existing consumer technology to collect and analyze robust real-world data for developing accurate machine learning tools. The advanced solutions could help identify biomarkers and predict the symptoms of various mental health problems, including anxiety and depression. 

 

The clinical study derived real-world data could help better understand various factors behind mental health illnesses as well as support the designing of digital tools for supporting individuals with mood disorders as well as clinicians providing care. 

 

Mind Medicine (MindMed) is a psychedelic medicine biotech company that develops medicines and therapies for people suffering from behavioral disorders and mental health problems. The company has been building the most compelling drug pipeline in psychedelics following novel-treatment paradigms to approach illnesses. Sphere Health provides FDA-approved and modern mental health services to self-funded employers. 

 

Addressing the partnership, MindMed’s Chief Medical Officer commented, “We are thrilled to have Sphere Health as a partner in this endeavor. As the ways in which individuals use technology to access care continues to evolve, so can our understanding of mental illness and mental health. The use of technology has the potential to offer a level of sensitivity and precision which does not currently exist in our models of these disorders and, we hope, will ultimately lead to better outcomes in our ability to help the folks who suffer from them.”

On the strategic partnership between two firms, TechSci Research’s Director said, “With rapid surge in mental health disorders and growing awareness towards them through education and advocacy, leading players of global health market are creating alliances to develop new tools and technologies for enhancing care. Besides, the key players are investing heavily in research and development activities to develop innovative products to meet the evolving demands of consumers.”

According to TechSci Research report on “Global Psychobiotics Market By Type (Food Supplements, Nutritional Supplements, Specialty Nutrients, Infant Formula) By Psychotropic Agent (Streptococcus, Bifidobacterium, Lactobacillus, Clostridium, Others) By Form (Powder, Liquid/Fluid, Tablets) By Distribution Channel (Retail Shops, Hypermarkets/Supermarkets, Drug Store/Pharmacy, Online) By Application (Gastrointestinal Function, Antidepressant, Anxiolytic, Autism Spectrum Disorder, Attention Deficit Hyperactivity Disorder, Schizophrenia, Others) By Region, Competition Forecast & Opportunities, 2026”, the global psychobiotics market is anticipated to grow at a formidable rate during the forecast period. The growth can be attributed to the increasing demand of probiotics for psychological ailments as well as rising incidences of anxiety and depression. Besides, health woke population educated and informed about psychobiotics and their easy availability are propelling the growth of global psychobiotics market.